Stock Track | Harrow Health Plunges 5.30% Pre-market Following Q3 Earnings and Revenue Miss

Stock Track2025-11-11

Harrow Health Inc (HROW) shares tumbled 5.30% in pre-market trading on Tuesday, extending the losses from Monday's after-hours session. The continued decline comes in the wake of the company's disappointing third-quarter 2025 financial results, which fell short of analysts' expectations.

The specialty pharmaceutical company reported adjusted earnings per share (EPS) of $0.33, which, while beating the revised estimate of $0.26, fell significantly short of the initial Wall Street expectation of $0.22 per share. Revenue for the quarter came in at $71.638 million, missing the anticipated $73.705 million. This underperformance on both top and bottom lines appears to have shaken investor confidence.

Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. Despite the setback, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction. However, the market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading begins on Tuesday, all eyes will be on Harrow Health to see if it can recover from this pre-market plunge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133600343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133600343","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Plunges 5.30% Pre-market Following Q3 Earnings and Revenue Miss","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) shares tumbled 5.30% in pre-market trading on Tuesday, extending the losses from Monday's after-hours session. The continued decline comes in the wake of the company's disappointing third-quarter 2025 financial results, which fell short of analysts' expectations.</p>\n\n<p>The specialty pharmaceutical company reported adjusted earnings per share (EPS) of $0.33, which, while beating the revised estimate of $0.26, fell significantly short of the initial Wall Street expectation of $0.22 per share. Revenue for the quarter came in at $71.638 million, missing the anticipated $73.705 million. This underperformance on both top and bottom lines appears to have shaken investor confidence.</p>\n\n<p>Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. Despite the setback, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction. However, the market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading begins on Tuesday, all eyes will be on Harrow Health to see if it can recover from this pre-market plunge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Plunges 5.30% Pre-market Following Q3 Earnings and Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Plunges 5.30% Pre-market Following Q3 Earnings and Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) shares tumbled 5.30% in pre-market trading on Tuesday, extending the losses from Monday's after-hours session. The continued decline comes in the wake of the company's disappointing third-quarter 2025 financial results, which fell short of analysts' expectations.</p>\n\n<p>The specialty pharmaceutical company reported adjusted earnings per share (EPS) of $0.33, which, while beating the revised estimate of $0.26, fell significantly short of the initial Wall Street expectation of $0.22 per share. Revenue for the quarter came in at $71.638 million, missing the anticipated $73.705 million. This underperformance on both top and bottom lines appears to have shaken investor confidence.</p>\n\n<p>Chief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. Despite the setback, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction. However, the market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading begins on Tuesday, all eyes will be on Harrow Health to see if it can recover from this pre-market plunge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1133600343","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133600343","pubTimestamp":1762857978,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc (HROW) shares tumbled 5.30% in pre-market trading on Tuesday, extending the losses from Monday's after-hours session. The continued decline comes in the wake of the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|哈罗健康第三季度盈利和营收未达预期盘前暴跌5.30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) shares tumbled 5.30% in pre-market trading on Tuesday, extending the losses from Monday's after-hours session. The continued decline comes in the wake of the company's disappointing third-quarter 2025 financial results, which fell short of analysts' expectations.\nThe specialty pharmaceutical company reported adjusted earnings per share (EPS) of $0.33, which, while beating the revised estimate of $0.26, fell significantly short of the initial Wall Street expectation of $0.22 per share. Revenue for the quarter came in at $71.638 million, missing the anticipated $73.705 million. This underperformance on both top and bottom lines appears to have shaken investor confidence.\nChief Executive Mark Baum attributed part of the underperformance to worse-than-expected results for Triesence, a steroid used to treat several eye diseases. Despite the setback, Baum remained optimistic, stating that he expects Triesence to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction. However, the market's reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading begins on Tuesday, all eyes will be on Harrow Health to see if it can recover from this pre-market plunge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133600343","isCrawlerRequest":true}